(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 July 2011 (28.07.2011)

PCT

(10) International Publication Number
WO 2011/091279 A2

(51) International Patent Classification:
A61K 39/155 (2006.01)

(21) International Application Number:
PCT/US2011/022094

(22) International Filing Date:
21 January 2011 (21.01.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/297,109 21 January 2010 (21.01.2010) US

(71) Applicant *(for all designated States except US)*: **LIGOCYTE PHARMACEUTICALS, INC.** [US/US]; 2155 Analysis Drive, Bozeman, MT 59718 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **STEADMAN, Bryan** [US/US]; c/o LIGOCYTE PHARMACEUTICALS, INC., 2155 Analysis Drive, Bozeman, MT 59718 (US). **TAYLOR, Ross** [US/US]; c/o LIGOCYTE PHARMACEUTICALS, INC., 2155 Analysis Drive, Bozeman, MT 59718 (US).

(74) Agents: **MCLEOD, Bonnie, Weiss** et al.; Cooley LLP, 777 6th Street, N.W., Suite 1100, Washington, DC 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: TARGETED HETEROLOGOUS ANTIGEN PRESENTATION ON CALICIVIRUS VIRUS-LIKE PARTICLES



(57) **Abstract**: The present invention provides particle-forming chimeric proteins comprising a Calicivirus capsid protein and one or more heterologous antigen sequences. In particular, the present invention discloses engineered Calicivirus capsid protein sequences containing heterologous epitopes fused at internal locations such that the modified capsid proteins retain the ability to form virus-like particles when expressed in host cells. Virus-like particles comprising the chimeric proteins and vaccine formulations are also described.

WO 2011/091279 A2